Podcast

Unique Approaches to the Management of Underserved Patients with IBD

Launch Date
01/25/2021
Credit Amount
0.00 Expired
Credit Expires
02/25/2022

Faculty

Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Digestive Disease and Surgery Chair, Department of Gastroenterology, Hepatology, and Nutrition The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Professor, Department of Medicine Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Cleveland, OH
Miguel Regueiro, MD, AGAF, FACG, FACP

Miguel Regueiro earned his bachelor’s degree at the University of Pennsylvania, his medical degree at Drexel (Hahnemann) University and completed his internal medicine internship, residency, and clinical and research fellowship training in gastroenterology at Harvard Medical School’s Beth Israel Hospital.

Dr. Regueiro was Professor of Medicine and Clinical and Translational Science at the University of Pittsburgh School of Medicine from 2000 to 2018. There he served as the IBD Clinical Medical Director, Senior Medical Lead of Specialty Medical Homes, was Professor with Tenure, and honored as the UPMC Endowed Chair for Patient Centered Care in Inflammatory Bowel Diseases.

Dr. Regueiro is currently the Chair of the Department of Gastroenterology and Hepatology and Chair of the Digestive Disease and Surgery Institute at Cleveland Clinic in Ohio. He serves as Medical Co- Chair of Digestive Disease and Surgical Institute Research Governance committee and is Professor of Medicine at the Lerner College of Medicine, Cleveland Clinic.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases with a focus on the natural course of these diseases and postoperative prevention of Crohn’s disease. Recently, he has been involved in transformative medicine initiatives and developing new models of healthcare, including the first-of-its kind specialty medical home for IBD. Dr. Regueiro is investigating alternative models of care in population-based health that integrates patients, payers, providers, pharmaceutical industry, and other facets of healthcare delivery around these novel programs.

Sophie Balzora, MD, FACG
Clinical Associate Professor of Medicine, NYU Grossman School of Medicine
Division of Gastroenterology and Hepatology, NYU Langone Health New York, NY
Sophie Balzora, MD, FACG

Sophie M. Balzora MD, FACG, is a Clinical Associate Professor at the NYU Grossman School of Medicine. Dr. Balzora has focused her academic efforts on improving physician engagement and enhancing the patient experience through objective structured clinical exams (OSCEs). She is Vice Chair of the American College of Gastroenterology (ACG) Diversity, Equity, and Inclusion Committee; Co-founder of ACG’s #DiversityinGI Social Media Campaign; and former Chair of the ACG Public Relations Committee. Dr. Balzora also serves on the Patient Education Sub-Committee of the Crohn’s and Colitis Foundation (CCF)’s National Scientific Advisory Committee, the social media team of CCF’s Inflammatory Bowel Diseases (IBD) Journal, Fight CRC’s Health Equity Committee, and the Gastroenterology Intersociety Group on Diversity (IGD), comprised of leadership representatives from the four major national gastroenterology societies. She has recently been accepted into the inaugural cohort of the Office of Diversity Affairs’ Faculty Leadership Development Program through the NYU Langone Academy, and is a 2020 recipient of the ACG Presidents Special Recognition Award for efforts in leadership, exemplary service, and guidance promoting diversity, equity, and inclusion. Dr. Balzora currently resides in New York City with her husband and daughter.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Additional Formats

Statement of Need

There are many disparities in irritable bowel disease (IBD) care, with an incidence rate of IBD hospitalization that is 4x higher in patients with low socio-economic status and a 3x increased ratio of IBD hospitalizations and mortality in Blacks compared to Whites and Hispanics.

The final episode of this CMEOCast podcast series summarizes the discussion points on the racial/ethnic and economic inequality in IBD and offers approaches to mitigate disparities on the level of both individual health care providers and systems. Expert faculty discuss the downstream effects of structural racism, offer tips for utilizing telehealth to engage minorities, and go over the interventions to increase treatment adherence.

Learning Objectives

At the end of this CME/CE activity, participants should be able to initiate multidisciplinary collaboration to provide medically underserved children, adolescents, and adults with IBD with guideline-recommended care.

Financial Support

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

Physicians, nurse practitioners, PAs, nurses, and pharmacists

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Regueiro reports that he receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on the advisory boards or a consultant for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Dr. Balzora reports that she is a consultant for Pfizer Inc.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Michael J. Franks, MSN, AGACNP-BC, FNP-BC (peer reviewer) has no disclosures to report.

Olga Askinazi, PhD (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.

Additional Formats

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

 

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-033-H01-P

 

PD-042-022521-90 

Related Activities

Gastroenterology

IBD Medical Home Interview

Learn More
Gastroenterology

Treatment of Ulcerative Colitis for Improved Patient Outcomes and Quality of Life

Learn More
Dermatology
04/12/2023

Managing Your Patients with Psoriasis and IBD: A Conversation with the Experts

1.0
Begin Learn More
Unique Approaches to the Management of Underserved Patients with IBD
Event Date: 01/25/2021
Begin